SCHEMBL4941379

SCHEMBL4941379

CC(=O)OC[Si](C)(C)O[Si](C)(C)COC(C)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.43
LMNA P02545 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CHRM5 P08912 2/20 0.36
CHRM1 P11229 2/20 0.36
CHRM3 P20309 2/20 0.36
TSHR P16473 2/20 0.36
PGR P06401 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
HTR1A P08908 1/20 0.36
CHRNB2 P17787 1/20 0.36
TBXA2R P21731 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA7 P36544 1/20 0.36
CHRNA4 P43681 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CHRNA10 Q9GZZ6 1/20 0.36
CHRNA9 Q9UGM1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18219809 0.91 ALDH1A1 (0.37) ALDH1A1LMNAHSD17B10CHRM5CHRM1
SCHEMBL11324715 0.90 ALDH1A1 (0.40) ALDH1A1LMNAHSD17B10CHRM5CHRM1
SCHEMBL523852 0.82 ALDH1A1 (0.42) ALDH1A1LMNAHSD17B10CHRM5CHRM1
SCHEMBL2303044 0.82 ALDH1A1 (0.42) ALDH1A1LMNAHSD17B10CHRM5CHRM1
SCHEMBL2409855 0.78 ALDH1A1 (0.50) ALDH1A1LMNAHSD17B10CHRM5CHRM1
SCHEMBL8422452 0.78
SCHEMBL2528318 0.78
SCHEMBL332509 0.77 TSHR (0.47) ALDH1A1TSHRTDP1
SCHEMBL8422450 0.76
SCHEMBL3475630 0.74 ALDH1A1 (0.43) ALDH1A1LMNAHSD17B10CHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230000993-A1 SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME BLINKBIO INC (US) 2023-01-05 US disclosed
US-11291731-B2 Silicon based drug conjugates and methods of using same BLINKBIO, INC. (US) 2022-04-05 US disclosed
US-9931407-B2 Silicon based drug conjugates and methods of using same BLINKBIO, INC. (US) 2018-04-03 US disclosed
US-9809677-B2 Polycarbonate composition and article comprising the same LG CHEM, LTD. (KR) 2017-11-07 US disclosed
US-20170202970-A1 SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME BLINKBIO, INC. 2017-07-20 US disclosed
US-20170202970-A1 SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME BLINKBIO, INC. 2017-07-20 US disclosed
WO-2016183359-A1 SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME BLINKBIO, INC. (US) 2016-11-17 WO disclosed
US-20160326321-A1 POLYCARBONATE COMPOSITION AND ARTICLE COMPRISING THE SAME LG CHEM, LTD. (KR) 2016-11-10 US disclosed
US-7851524-B2 Antistatic agents, compositions thereof, and methods of manufacture SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2010-12-14 US disclosed
US-7569714-B2 Antistatic and antidust agents, compositions thereof, and methods of manufacture SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2009-08-04 US disclosed
US-20090184442-A1 ANTISTATIC AGENTS, COMPOSITIONS THEREOF, AND METHODS OF MANUFACTURE SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2009-07-23 US disclosed
US-20080075981-A1 Magnetic recording medium HITACHI MAXELL, LTD. (JP) 2008-03-27 US disclosed
EP-0700951-B1 Polyorganosiloxane and process for producing the same SHOWA DENKO KK (JP) 2000-12-27 EP disclosed
EP-0700951-A1 Polyorganosiloxane and process for producing the same SHOWA DENKO KABUSHIKI KAISHA (JP) 1996-03-13 EP disclosed
US-5491203-A COMPRISES POLYSILSESQUIOXANE STRUCTURE; HAS METHYL GROUP AND A REACTIVE GROUP ON SIDE CHAINS; SUITABLE AS POLYMER MODIFIER; CROSSLINKING; COATINGS SHOWA DENKO K. K. (JP) 1996-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170202970-A1 SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME CD44, MSN, AS3MT ALDH1A1 2151/4885LMNA 3473/4885HSD17B10 3435/4885
US-11291731-B2 Silicon based drug conjugates and methods of using same CD44, MSN, AS3MT ALDH1A1 2151/4885LMNA 3473/4885HSD17B10 3435/4885
US-20230000993-A1 SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME CD44, MSN, AS3MT ALDH1A1 2151/4885LMNA 3473/4885HSD17B10 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.